Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 72.58% | -529.10% | 94.24% | -60.39% | -10.71% |
| Total Depreciation and Amortization | -1.81% | -0.90% | -5.11% | -42.48% | -5.85% |
| Total Amortization of Deferred Charges | 21.49% | -20.39% | 1.33% | 4.90% | -2.05% |
| Total Other Non-Cash Items | -551.03% | 88.53% | -164.03% | 319.13% | 76.38% |
| Change in Net Operating Assets | 199.75% | -36.98% | -145.77% | 449.55% | -122.97% |
| Cash from Operations | 30.26% | 4.60% | -67.54% | 41.74% | -42.31% |
| Capital Expenditure | -- | -- | -- | -- | -100.00% |
| Sale of Property, Plant, and Equipment | -100.00% | 231.03% | -98.14% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | 201.22% | -- | -100.00% | -13.01% |
| Cash from Investing | -100.00% | 201.73% | -1,718.92% | -94.69% | -13.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 40.00% | -25.00% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 72.08% | -- | -- | -- |
| Cash from Financing | -100.00% | 115.47% | -100.61% | 867,700.00% | -103.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -353.81% | 91.86% | -312.62% | 917.25% | -130.19% |